Celyad Oncology S.A.

Celyad Oncology S.A. is a biotechnology company focused on the discovery and development of cellular therapies for cancer treatment. Its primary function is to advance innovative therapies in the field of oncology, leveraging its proprietary technology platforms. The company specializes in Allogeneic Chimeric Antigen Receptor T-cell (CAR-T) research. This involves modifying T-cells to better recognize and eliminate cancer cells, potentially offering novel treatment options for patients suffering from serious malignancies. Celyad Oncology operates within the biotechnology and pharmaceutical sectors, playing a vital role in the advancement of next-generation immunotherapy solutions. Headquartered in Mont-Saint-Guibert, Belgium, the company is at the forefront of translational medicine, working to bridge the gap between laboratory research and clinical applications. By developing cutting-edge therapies, Celyad aims to contribute significantly to the growing field of personalized medicine, positioned within the dynamic and high-growth oncology treatment market.